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Selective Inhibition of Protein Kinase C 2 Attenuates
Inducible Nitric Oxide Synthase–Mediated
Cardiovascular Abnormalities in Streptozotocin-Induced
Diabetic Rats
Prabhakara Reddy Nagareddy, Hesham Soliman, Guorong Lin, Padmesh S. Rajput, Ujendra Kumar,
John H. McNeill, and Kathleen M. MacLeod
OBJECTIVE—Impaired cardiovascular function in diabetes is
partially attributed to pathological overexpression of inducible
nitric oxide synthase (iNOS) in cardiovascular tissues. We exam-
ined whether the hyperglycemia-induced increased expression of
iNOS is protein kinase C-2 (PKC2) dependent and whether
selective inhibition of PKC reduces iNOS expression and cor-
rects abnormal hemodynamic function in streptozotocin (STZ)-
induced diabetic rats.
RESEARCH DESIGN AND METHODS—Cardiomyocytes and
aortic vascular smooth muscle cells (VSMC) from nondiabetic
rats were cultured in low (5.5 mmol/l) or high (25 mmol/l)
glucose or mannitol (19.5 mmol/l mannitol  5.5 mmol/l glucose)
conditions in the presence of a selective PKC inhibitor,
LY333531 (20 nmol/l). Further, the in vivo effects of PKC
inhibition on iNOS-mediated cardiovascular abnormalities were
tested in STZ-induced diabetic rats.
RESULTS—Exposure of cardiomyocytes to high glucose acti-
vated PKC2 and increased iNOS expression that was prevented
by LY333531. Similarly, treatment of VSMC with LY333531 pre-
vented high glucose–induced activation of nuclear factor B,
extracellular signal–related kinase, and iNOS overexpression.
Suppression of PKC2 expression by small interference RNA
decreased high-glucose–induced nuclear factor B and extracel-
lular signal–related kinase activation and iNOS expression in
VSMC. Administration of LY333531 (1 mg/kg/day) decreased
iNOS expression and formation of peroxynitrite in the heart and
superior mesenteric arteries and corrected the cardiovascular
abnormalities in STZ-induced diabetic rats, an action that was
also observed with a selective iNOS inhibitor, L-NIL.
CONCLUSIONS—Collectively, these results suggest that inhibi-
tion of PKC2 may be a useful approach for correcting abnormal
hemodynamics in diabetes by preventing iNOS mediated nitro-
sative stress. Diabetes 58:2355–2364, 2009
C
ardiovascular complications are recognized to
be the major cause of morbidity and mortality
associated with diabetes (1). Activation of pro-
tein kinase C (PKC) isoforms, increased glucose
ﬂux through the polyol pathway, formation of advanced
glycation end products (AGE), and increased levels of
oxidative and nitrosative stress are some of the mecha-
nisms believed to be involved in the etiology of these
complications (2–4). Increasing evidence now implicates
the abnormal activation of PKC2, secondary to increased
formation of diacylglycerol (DAG) by hyperglycemia, in a
number of cardiovascular diabetes complications (3,5).
Studies from our lab (6,7) and elsewhere (5) have found
preferential increases in expression and/or activation of
the PKC2 isoform in cardiac and vascular tissues of
diabetic animals. Inhibition of the activity of PKC has
been shown to result in amelioration of diabetic nephrop-
athy and retinopathy in human patients (8,9) and was
recently reported to improve cardiac function in strepto-
zotocin (STZ)-induced diabetic rats (10). However, the
mechanisms by which activation of this PKC isoform exerts
adverse effects in cardiovascular tissues remain unclear.
A seminal study suggested that normalizing mitochon-
drial oxidative stress could prevent hyperglycemia-
induced activation of PKC, increased ﬂux through the
polyol pathway, and formation of AGE (2), underscoring
the importance of oxidative stress in the etiology of
diabetes complications. Previous studies from our lab
have demonstrated signiﬁcant improvements in cardiovas-
cular function of STZ-induced diabetic rats treated with
the antioxidant N-acetylcysteine in parallel with inhibition
of PKC2 activation (6) and reduction in inducible nitric
oxide synthase (iNOS)-mediated nitrosative stress (11).
Speciﬁcally, we found that improvements in cardiac per-
formance, mean arterial blood pressure (MABP), heart
rate, pressor responses to vasoactive agents, and endothe-
lial function were associated with improvements in oxida-
tive and nitrosative stress in the heart and arteries of
STZ-induced diabetic rats (11–13). However, it remains
unclear whether the increase in iNOS-mediated nitrosative
stress is an independent manifestation of hyperglycemic
injury or is linked to the activation of PKC2.
In the present study, we tested the hypothesis that
diabetes-induced activation of PKC2 causes cardiovascu-
lar abnormalities via induction of iNOS. First, we investi-
gated whether PKC2 induces iNOS expression in cardiac
and vascular tissues and the mechanisms involved therein,
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siRNA. Second, we investigated the functional signiﬁcance
of this in vivo by determining the effects of treatment of
STZ-induced diabetic rats with LY333531 on iNOS expres-
sion, nitrotyrosine formation, and hemodynamic abnor-
malities. Our results suggest that induction of iNOS, and
consequently increased nitrosative stress, is one of the
mechanisms by which PKC2 leads to cardiovascular
complications in diabetes.
RESEARCH DESIGN AND METHODS
Study design and induction of diabetes. This study conforms to the
Canadian Council on Animal Care Guidelines on the Care and Use of
Experimental Animals and was approved by the University of British Colum-
bia Animal Care Committee. Forty-eight male Wistar rats weighing between
280 and 300 g were obtained from Charles River Laboratories, Quebec, and
allowed to acclimatize to the local vivarium. They were randomly divided into
six equal groups: control, control treated with LY333531 or L-NIL, diabetic,
and diabetic treated with LY333531 or L-NIL. Diabetes was induced by a single
tail vein injection of 60 mg/kg STZ whereas control animals received equal
volume of citrate buffer. The presence of diabetes was conﬁrmed by hyper-
glycemia (20 mmol/l) 72 h after STZ administration. Plasma glucose was
measured using an enzymatic colorimetric assay kit (Roche Diagnostics) and
a Beckman Glucose Analyzer. One week after the induction of diabetes,
animals received vehicle or the selective PKC inhibitor, LY333531 (1 mg/kg/
day) (14), or the selective iNOS inhibitor, L-NIL (3 mg/kg/day), by oral gavage.
LY333531 is a potent and speciﬁc inhibitor of PKC with an IC50 of 5 nmol/l
for the -isozymes, which is 100-fold lower than for the , ,o r-isoforms of
PKC (15). Similarly, L-NIL is a potent and relatively selective iNOS inhibitor
with an IC50 of 5.9 	mol/l for iNOS compared with an IC50 of 138 	mol/l for
eNOS and 35 	mol/l for nNOS (16). A dose of 3 mg/kg/day was selected based
on our previous study in which we were able to inhibit iNOS-mediated NO
production in heart tissues from STZ-induced diabetic rats (17). After 3 weeks
of treatment, each animal was surgically prepared for measurement of MABP,
heart rate, and pressor responses to methoxamine.
Surgical procedures and hemodynamic measurements. Animals were
surgically prepared as described previously (18). For more information, please
refer to the online appendix (available in an online appendix at http://
diabetes.diabetesjournals.org/content/early/2009/07/08/db09-0432/suppl/DC1).
Collection of tissue samples. After hemodynamic measurements, animals
were killed with an overdose of pentobarbital (100 mg/kg). The heart and
superior mesenteric arteries (SMA) were immediately removed and placed in
ice-cold Krebs solution (120 mmol/l NaCl, 5.9 mmol/l KCl, 25 mmol/l NaHCO3,
11.5 mmol/l glucose, 1.2 mmol/l NaH2PO4, 1.2 mmol/l MgCl2, and 2.5 mmol/l
CaCl2) containing 0.1 	mol/l water-soluble dexamethasone to prevent induc-
tion of iNOS in vitro. The tissues were cleaned of all adherent tissue, snap
frozen in liquid nitrogen, and stored at 
70°C for Western blot measurements.
Some tissue sections were preserved in neutral buffered formalin for immu-
nohistochemistry experiments.
Preparation of isolated rat ventricular cardiomyocytes. Ca
2-tolerant
cardiomyocytes were isolated as described previously (19) (see online
appendix).
Preparation and culture of rat aortic vascular smooth muscle cells.
Please see online appendix.
PKC2 siRNA studies in rat aortic vascular smooth muscle cells. Small
interference RNA (siRNA) speciﬁc to rat PKC2 was used to knock down the
expression of PKC2 in rat aortic vascular smooth muscle cells (VSMCs). The
PKC2 siRNA, which was custom made by Santa Cruz Biotech (Santa Cruz,
CA), consisted of a pool of three target-speciﬁc 19–25 nitrotyrosine siRNA
duplexes. The transfection reagent, medium, and scrambled siRNA were also
purchased from Santa Cruz Biotech. For optimal siRNA transfection, the
manufacturer’s protocol was followed. Brieﬂy, VSMCs were seeded in a
six-well plate and cultured in 2 ml antibiotic-free Dulbecco’s modiﬁed Eagle’s
medium (DMEM) supplemented with 10% FBS until the cells were 60–80%
conﬂuent (36 h). On the day of transfection, cells were washed with
transfection medium and incubated with 1 ml of transfection reagent contain-
ing 60 pmols of either MOCK (scrambled) or rat-speciﬁc PKC2 siRNA
oligonucleotides for 16 h. The medium was then supplemented with 1 ml of
fresh DMEM (containing 2 FBS and antibiotics) for another 24 h. At this
point, the cells were washed with warm PBS and treated with either low or
high glucose containing DMEM for another 48 h in the presence or absence of
various drugs as mentioned in the RESULTS section.
Immunoprecipitation and Western blot analysis. Please see online
appendix.
Immunohistochemistry and quantiﬁcation of iNOS and nitrotyrosine
immunostain in the heart and superior mesenteric artery sections.
Please see online appendix.
Measurement of oxidative stress in VSM cells. Please see online
appendix.
Statistical analysis. All values are expressed as means  SE. Statistical
analysis was performed using one-way ANOVA followed by the Newman-
Keuls test for multiple comparisons. GraphPad Prism (GraphPad Software)
software program was used for statistical analysis. For all results, the level of
signiﬁcance was set at P 
 0.05.
RESULTS
Effect of LY333531 on PKC2 and iNOS expression in
cardiomyocytes and diabetic hearts. We previously
have shown increased expression of iNOS in hearts (18)
and cardiomyocytes (17) isolated from diabetic rats. In the
present study, we examined whether incubation of normal
cardiomyocytes in high glucose increases iNOS expression
and, if so, whether this could be prevented by treatment
with the PKC inhibitor, LY333531. Treatment of cardio-
myocytes with high glucose (25 mmol/l) for 18 h had no
effect on total levels of PKC2 but signiﬁcantly increased
levels of Thr
641-phosphorylated PKC2 (Fig. 1A). Phos-
phorylation of Thr
641 is crucial for the appropriate subcel-
lular localization and catalytic function of PKC2 and is
often used as an index of PKC2 activation (20). On the
other hand, exposure of cardiomyocytes to mannitol (19.5 
5.5 mmol/l glucose) to determine any effects because of
hyperosmolarity did not alter levels of either Thr
641-
phosphorylated or total PKC2 compared with cells
treated with low glucose (data not shown). Treatment of
cardiomyocytes with LY333531 prevented the high glu-
cose–induced increase in the phosphorylation of PKC2
without affecting the expression of total PKC2 (Fig. 1A).
Further, high glucose also increased the expression of
iNOS in isolated cardiomyocytes, and this was prevented
by pretreatment with LY333531 (Fig. 1B). Similarly, there
was a signiﬁcant increase in the expression of iNOS and in
levels of Thr
641 phosphophorylated PKC2 without any
change in total PKC2 in hearts from untreated diabetic
rats. Treatment of diabetic rats with LY333531 signiﬁcantly
reduced levels of phosphorylated PKC2 as well as iNOS
expression without affecting these parameters in age-
matched control rat hearts (Fig. 2).
Effect of LY333531 on PKC2 and iNOS expression in
VSMC and superior mesenteric arteries. We next de-
termined whether iNOS expression was induced in rat
aortic VSMC cultured in high glucose as well as in superior
mesenteric arteries from diabetic rats. Similar to that
observed in diabetic rat hearts, there was a signiﬁcant
increase in the expression of iNOS in mesenteric arteries
from untreated diabetic rats. Treatment of diabetic rats
with LY333531 signiﬁcantly reduced the expression of
iNOS in mesenteric arteries (Fig. 3A). Further, incubation
of VSMC in high glucose (Fig. 3B) but not mannitol (Fig.
1B, available in an online appendix) for 36 h also signiﬁ-
cantly increased iNOS expression. Activation of PKC2, as
measured by increased phosphorylation of Thr
641 was
signiﬁcantly elevated in high glucose conditions (Fig. 3C).
Treatment of VSMC with LY333531 not only reduced the
phosphorylation of PKC2 (Fig. 3C), consistent with inhi-
bition of its activation, but also prevented the increase in
iNOS expression (Fig. 3B).
Induction of iNOS is PKC2 dependent in VSM cells.
Our experiments so far indicated that exposure of VSMC
and cardiomyocytes to high glucose leads to an increase in
iNOS expression that is prevented by the PKC inhibitor,
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required for induction of iNOS, we suppressed its expres-
sion in VSMC using rat-speciﬁc PKC2 siRNA and again
exposed the cells to low and high glucose conditions.
Although we were not able to suppress the expression of
PKC2 completely, a reduction in PKC2 protein expres-
sion of 50% (Fig. 4A) not only reduced the phosphoryla-
tion of PKC2 to levels found in normal glucose but also
prevented the increase in expression of iNOS in VSMC
exposed to high glucose (Fig. 4B) while having no effect on
iNOS expression in VSMC incubated in low glucose. Levels
of other PKC isoforms, including PKC, 1, , and ε , were
unaffected by PKC2 siRNA treatment (Fig. 6, available in
an online appendix).
Induction of iNOS by PKC2 involves extracellular
signal–related kinase 1/2 and nuclear factor-B acti-
vation in VSMC. Because extracellular signal–related
kinase (ERK)1/2 has been reported to mediate increased
expression of iNOS in vascular smooth muscle via the
nuclear factor (NF)-B pathway (21,22), we next investi-
gated whether ERK was activated in cells exposed to high
glucose. Incubation of VSMC in high glucose (Fig. 5A)
but not mannitol (Fig. 1C, available in an online appen-
dix) increased ERK activity as measured by increased
phosphorylation of both ERK-1 and ERK-2 at Thr
202 and
Tyr
204, respectively. Further, treatment of VSMC ex-
posed to high glucose with LY333531 signiﬁcantly pre-
vented ERK activation (Fig. 5A). Similarly, in superior
mesenteric arteries from untreated diabetic rats, we
found a signiﬁcant increase in ERK activity, which was
prevented by treatment with LY333531 (Fig. 4, available
in an online appendix).
The signaling events that lead to NF-B activation
involve phosphorylation, ubiquitination, and proteolytic
degradation of IB- from its inactive trimeric complex of
IB/p65/p50 in the cytosol. This is followed by transloca-
tion of the active dimer (p65/p50) to the nucleus, where it
binds to speciﬁc regions within the promoter to initiate
iNOS message transcription (23). To assess NF-B activa-
tion, we measured the phosphorylation of Ser
536 on the
p65 subunit of NF-B. Exposure of VSMC to high glucose
but not mannitol increased the phosphorylation of the
NF-B p65 subunit, and this was inhibited by pretreatment
with LY333531 (Fig. 5B). The expression of total NF-B
p65 subunit was similar in all groups except the mannitol
group where it was increased. However, this increase was
not reduced by treatment with LY333531, indicating that
the hyperosmotic signal leading to increased synthesis of
NF-B P65 protein is not PKC2 dependent (Fig. 1D,
available in an online appendix).
To conﬁrm the speciﬁc involvement of the PKC2 iso-
form in the activation of ERK1/2 and NF-B, we incubated
PKC2 siRNA–transfected VSMC in high glucose. VSMC in
which PKC2 was suppressed failed to show activation of
ERK 1/2 and NF-B on exposure to high glucose levels
(Fig. 6). These data clearly suggest that PKC2 is the
predominant isoform involved in the activation of NF-B
by ERK1/2 in VSMC exposed to high glucose.
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FIG. 1. LY333531 treatment decreases PKC2 phosphorylation and iNOS in cardiomyocytes. A:( top) Representative Western blot showing
phospho-PKC2 (Thr
641) in comparison with total PKC2 in cardiomyocytes exposed to low glucose (LG; 5.5 mmol/l) or high glucose (HG; 25
mmol/l) for 18 h in the absence or presence of LY333531 (LY333531; 20 nmol/l). (bottom) The densitometric values of phospho-PKC2 were
normalized to corresponding total PKC2 densitometric values and the relative band intensities are expressed as means  SE (n  4 independent
experiments). *P < 0.05 compared with low glucose, low glucose  LY333531, and high glucose  LY333531 groups. B: Representative Western
blot showing iNOS expression, with glyceraldehyde-3-phosphate dehydrogenase (GADPH) as a loading control, in cardiomyocytes exposed to low
(5.5 mmol/l) or high glucose (25 mmol/l) for 18 h in the presence or absence of LY333531 (20 nmol/l). iNOS densitometric values were normalized
to their corresponding GAPDH densitometric values and expressed as relative band intensities. All data are expressed as means  SE (n  3t o
5 independent experiments). *P < 0.05 compared with low glucose, low glucose  LY333531, and high glucose  LY333531 groups.
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stress in VSMC. VSMC exposed to high glucose produced
a signiﬁcant increase in the generation of superoxide
anion free radicals as measured by dihydroerthidium
ﬂuorescence. Treatment of VSMC with LY333531 not only
inhibited the high glucose–induced increase in oxidative
stress but also reduced superoxide anion production in
low glucose, suggesting an inherent antioxidant effect of
the inhibitor (Fig. 5, available in an online appendix).
In vivo effects of LY333531 on PKC2, iNOS, and
nitrotyrosine expression in the heart and mesenteric
arteries. Rats were made diabetic with STZ and were
treated with LY333531 (1 mg/kg/day) or L-NIL (3 mg/kg/
day) by oral gavage for 3 weeks. Previous studies have
shown the effectiveness of these doses of the inhibitors in
STZ-induced diabetic rats (17,18,24). At the end of the
treatment period, untreated diabetic rats had signiﬁcantly
elevated blood glucose levels and reduced body weights
compared with control rats, which were not altered by
LY333531 or L-NIL treatment (Table 1).
As explained in previous sections, heart and mesenteric
arteries from untreated diabetic rats showed increased
phosphorylation of PKC2 and iNOS expression, which
was signiﬁcantly inhibited by treatment with LY333531
(Fig. 2 and Fig. 3). Further, immunohistochemical analysis
revealed increased expression of iNOS in the cardiomyo-
cytes of heart sections and the medial and advential layers
of superior mesenteric artery sections (Fig. 2, available in
an online appendix) from untreated diabetic rats. In supe-
rior mesenteric arteries, as opposed to the dense immu-
nostaining in the medial and advential layers, very little
staining was observed in the tunica intima or endothelium,
suggesting that the major source of iNOS is the media and
adventia. Semiquantitative analysis of iNOS immunostain
in the photomicrographs suggests a reduction of iNOS
expression by 50% in both the heart and superior mes-
enteric arteries of diabetic rats treated with LY333531.
Similarly, immunohistochemical analysis of nitrotyrosine,
an indirect marker of peroxynitrite formation, indicated an
increase in the nitration of proteins in the hearts and
superior mesenteric arteries (Fig. 3, available in an online
appendix) of untreated diabetic rats. As shown, there is a
substantial increase in the levels of nitrotyrosine in the
diabetic heart (60%) and arteries (40%) compared with
those in control rats. Treatment with LY333531 signiﬁ-
cantly decreased the formation of nitrotyrosine in diabetic
rats compared with untreated diabetic rats both in supe-
rior mesenteric arteries and in ventricular muscle.
Effect of PKC and iNOS inhibition on cardiovascu-
lar function in diabetic rats. We previously have shown
that direct inhibition of iNOS by L-NIL in vivo signiﬁcantly
improved cardiac performance, pressor responsiveness,
and endothelial function in STZ-induced diabetic rats
(17,18). In the present study, we examined the in vivo
effects of PKC inhibition on iNOS-mediated cardiovascu-
lar abnormalities in these animals. Four weeks after the
induction of diabetes, untreated diabetic rats showed
signiﬁcantly lower MABP (Fig. 7A) and heart rate (Fig. 7B)
compared with age-matched control rats. Treatment with
LY333531 or L-NIL signiﬁcantly prevented the depression
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FIG. 2. Effect of LY333531 (LY)on PKC2 phosphorylation and iNOS expression in control and diabetic heart tissues. A: Representative Western
blot showing phospho-PKC2 (Thr
641) in comparison with total PKC2 expression levels in ventricular tissues of control (C), diabetic (D),
control LY333531-treated (C-LY), and diabetic LY333531-treated (D-LY) rats. The densitometric values of phospho-PKC2 were normalized to
corresponding total PKC2 expression levels and the relative band intensities are expressed as means  SE (n  5). *P < 0.05 compared with
C, C-LY, and D-LY groups. B: Representative Western blot showing iNOS expression in the ventricular tissues of C, D, C-LY, and D-LY groups. iNOS
protein was immunoprecipitated from heart ventricular tissue lysates using mouse monoclonal anti-iNOS antibody. Equal amounts of
immunoprecipitated complex were loaded on to the gels and were subjected to SDS-PAGE. Densitometric data are expressed as percentage of
control. All values are expressed as means  SE (n  4). *P < 0.05 compared with C, C-LY, and D-LY groups.
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affecting these parameters in control animals. Further,
administration of bolus doses of methoxamine (100–300
nmoles/kg) increased MABP in both control and diabetic
rats in a dose-dependent manner. Compared with the
corresponding age-matched control rats, responses to
methoxamine were signiﬁcantly attenuated in untreated
diabetic rats (Fig. 7D). However, treatment of diabetic
rats with LY333531 or L-NIL signiﬁcantly augmented
pressor responses to methoxamine while having no
effect in control rats. Endothelial function was tested
using a single bolus dose of L-NAME. As shown (Fig.
7C), untreated diabetic rats exhibited attenuated pres-
sure response (MABP) to L-NAME suggesting an im-
pairment of endothelial function. Treatment with L-NIL
but not LY333531 signiﬁcantly improved endothelial
function in diabetic rats.
DISCUSSION
Numerous studies have led to the identiﬁcation of multiple
hyperglycemia-induced alterations in metabolism and signal-
ing that have been linked to activation of PKC and an
eventual increase in oxidative/nitrosative stress in diabetes
(2–4). It remains unclear whether the increase in nitrosative
stress, which is implicated in the etiology of diabetes second-
ary complications (4), is an independent manifestation of
hyperglycemic injury or is linked to the activation of PKC. In
the present study, we tested the hypothesis that high
glucose–induced activation of PKC2 increases iNOS-medi-
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FIG. 3. Effect of LY333531 (LY) on PKC activation and iNOS expression
in isolated superior mesenteric arteries and cultured rat aortic VSMC. A:
Representative Western blot showing iNOS expression in superior mes-
enteric arteries of control (C), diabetic (D), control LY333531-treated
(C-LY), and diabetic LY333531-treated (D-LY) groups. iNOS was immu-
noprecipitated from superior mesenteric artery tissue lysates using
mouse monoclonal anti-iNOS antibody. Densitometric data are expressed
as percentage of control. All values are expressed as means  SE (n  4).
*P < 0.05 compared with control (C), control LY333531-treated (C-LY),
and diabetic LY333531-treated (D-LY) groups;
#P < 0.05 compared with
control and control LY333531-treated. B: Representative Western blot
showing iNOS expression, with GAPDH shown as a loading control, in
aortic VSMC exposed to low glucose (LG; 5.5 mmol/l) and high glucose
(HG; 25 mmol/l) for 36 h in the presence or absence of LY333531 (20
nmol/l). iNOS densitometric values were normalized to their correspond-
ing GAPDH densitometric values and expressed as relative band intensi-
ties. All data are expressed as means  SE (n  4 independent
experiments). *P < 0.05 compared with low glucose, low glucose 
LY333531, and high glucose  LY333531 groups. C: Representative West-
ern blot showing phospho- and total PKC2 expression in VSMC exposed
to low (5.5 mmol/l) or high glucose (25 mmol/l) for 36 h in the presence or
absence of LY333531 (20 nmol/l). The densitometric values of phospho-
PKC2 were normalized to corresponding total PKC2 expressionlevels
and the relative band intensities are expressed as means  SE (n  4
independent experiments). *P < 0.05 compared with low glucose, low
glucose  LY333531, and high glucose  LY333531 groups.
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ties. The results of our investigation provide clear evidence
supporting this hypothesis because treatment with LY333531
or PKC2 siRNA inhibited the increased expression of iNOS
in cardiovascular tissues and LY333531 administration in
vivo protected diabetic animals from the deleterious cardio-
vascular effects of hyperglycemia. Furthermore, our results
demonstrate that PKC2 is essential for high glucose–in-
duced activation of ERK1/2 and NF-B and subsequent
induction of iNOS and that the protective effects of PKC2
inhibition in diabetes are associated with inhibition of
iNOS-mediated peroxynitrite formation.
High glucose is known to increase de novo synthesis of
DAG, which is a potent activator of PKC in many cellular
types (25,26). Elevated DAG levels have been reported in
various tissues including the heart, retina, and kidney of
diabetic rats (3,27). Furthermore, it is now established that
increased levels and activity of speciﬁc isoforms of PKC
occurs in the cardiovascular system in diabetes, and
evidence suggests that abnormal activation of the PKC
system contributes to the development of diabetes cardio-
vascular complications (3,5,28). However, understanding
the PKC signaling system is complicated by the presence
of a large number of isoforms each with varying cellular
distribution and sometimes opposing functions (29). The
isoform that has been most frequently implicated in dia-
betes cardiovascular complications (6,28,30) is PKC2 (5).
Studies from our lab and elsewhere have reported in-
creased membrane levels of PKC2 in hearts (6) and
superior mesenteric arteries (31) from diabetic rats.
Consistent with this, in the present study, we found
evidence for increased activation of PKC2 both in the
heart and superior mesenteric artery from diabetic rats
as well as in cardiomyocytes and VSMC exposed to high
glucose. Additionally, we found increased expression of
PKCε but not of the , 1,o r isoforms in VSMC
exposed to high glucose (Fig. 6, available in an online
appendix).
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FIG. 4. Effect of PKC2 suppression on PKC2 expression and activa-
tion and iNOS expression in VSMC. Cells were transfected with either
MOCK or PKC2-speciﬁc siRNA and exposed to low or high glucose for
36 h. A: Representative Western blot showing total and phospho-
PKC2 expression, with GAPDH as a loading control in VSMC treated
with MOCK or PKC2 siRNA. The densitometric values of PKC2 were
normalized to corresponding total GAPDH densitometric values and
the relative band intensities are expressed as means  SE (n  4).
Open bars represent low glucose–treated and dark bars represent high
glucose–treated VSMC. *P < 0.05 compared with MOCK siRNA–
treated VSMC exposed to low glucose or high glucose conditions, @P <
0.05 compared with all other groups. B: Representative Western blot
showing iNOS expression, with GAPDH as a loading control in VSMC
treated with MOCK or PKC2 siRNA. The densitometric values of
iNOS were normalized to corresponding total GAPDH densitometric
values, and the relative band intensities are expressed as means  SE
(n  4). Open bars represent low glucose–treated and dark bars
represent high glucose–treated VSMC. *P < 0.05 compared with all
other groups.
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as phorbol esters or PKC overexpression has been re-
ported to upregulate cytokine-induced increases in iNOS
and NO production in various cell types (32–34). These
studies, most of which were conducted in noncardiovas-
cular cell types, suggested the involvement of a variety of
PKC isoforms in the induction of iNOS in response to
proinﬂammatory cytokines (32–34). On the other hand,
high glucose–mediated increases in PKC have been vari-
ously reported to both inhibit (35) and to potentiate (36)
cytokine-induced increases in iNOS expression in VSMC.
Although the reason for the discrepancy between previous
studies is not clear, our data show that inhibition of PKC
attenuates iNOS expression both in isolated cardiomyo-
cytes and VSMC exposed to high glucose in culture and in
the heart and arteries of diabetic rats. This was conﬁrmed
using both pharmacological inhibition and silencing of
PKC2 in VSMC. To our knowledge, this study is the ﬁrst
to demonstrate the speciﬁc involvement of PKC2 in the
induction of iNOS in cardiovascular tissues and, most
importantly, its signiﬁcance in the development of diabetic
cardiovascular complications.
The mechanism by which PKC2 induces the expression
of iNOS in cardiovascular tissues likely involves ERK1/2
and NF-B, because the suppressive effect of LY333531 on
iNOS expression was accompanied by inhibition of ERK
and NF-B activation. Previous studies have shown that
inhibition of ERK activation, either by selective chemical
inhibitors or by antisense oligodeoxynucleotides, attenu-
ates NF-B activation and iNOS expression in VSMC
stimulated with cytokines (21,22). Several cell types are
known to increase ERK and NF-B activity when exposed
to high glucose, and persistently higher levels of NF-B
have been reported in target organs such as the retina, the
heart, and the kidney of diabetic rats (37,38). In agreement
with these observations, we also found increased ERK
activity in arteries (Fig. 4, available in an online appendix)
of STZ-induced diabetic rats. Taken together, our data and
the results of previous studies support the view that high
glucose–induced activation of PKC2 increases iNOS ex-
pression by ERK activation of NF-B (21,22,37).
Although it is unclear how PKC2 activates the ERK–
NF-B pathway, the mechanism may involve the formation
of reactive oxygen species (ROS) secondary to PKC activa-
tion (2,39). In the present study, exposure of VSMC to high
glucose produced a signiﬁcant increase in ROS that was
prevented by treatment with LY333531. The evidence that
LY333531 inhibits ERK and NF-B at the same time that it
decreases ROS production suggests the possibility that ROS
are central to activation of this pathway. Indeed, ROS are
known to directly activate NF-B, a pleiotropic oxidant–
sensitive transcriptional factor, as well as ERK (40,41).
Studies from our lab and elsewhere have demonstrated
increased levels of oxidative and nitrosative stress in
STZ-induced diabetic rats, and treatment with either an
antioxidant or iNOS inhibitor has reduced nitrotyrosine
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FIG. 5. Effect of LY333531 (LY) on ERK1/2 and NF-B activation in VSMC. A: Representative Western blot showing phospho-ERK-1 (Thr
202) and
phospho-ERK-2 (Tyr
204) in comparison with total ERK1/2 and with GAPDH as a loading control in VSMC exposed to low glucose (LG; 5.5 mmol/l)
or high glucose (HG; 25 mmol/l) for 36 h in the presence or absence of LY333531 (20 nmol/l). The densitometric values of phospho ERK-1 were
normalized to corresponding total ERK-1densitometric values and the relative band intensities are expressed as means  SE (n  4 independent
experiments). *P < 0.05 compared with all other groups. B: Representative Western blot showing phospho-NF-B P65 subunit (Ser
536)i n
comparison with total NF-B P65 and with GAPDH as a loading control in VSMC exposed to low (5.5 mmol/l) and high (25 mmol/l) glucose for
36 h in the presence or absence of LY333531 (20 nmol/l). The densitometric values of phospho-NF-B were normalized to corresponding total
phospho-NF-B P65densitometric values and the relative band intensities are expressed as means  SE (n  4 independent experiments). *P <
0.05 compared with all other groups.
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(11,18). Peroxynitrite has been shown to cause severe
hypotension, profound vasodilatation, cardiac depression,
and multiple organ failure in various models of septic
shock (42). Increasing evidence suggests that many of the
cardiovascular abnormalities in diabetic rats can be pre-
vented by inhibiting nitrosative stress caused by peroxyni-
trite (43,44). For instance, previous studies from our lab
showed that inhibition of peroxynitrite using antioxidants
such as N-acetylcysteine improves cardiac performance,
MABP, and heart rate in STZ-diabetic rats (6,11).
Increasing evidence now suggests that iNOS and nitrosa-
tive stress are critical determinants in the development of
diabetes complications in humans (4,45,46). Increased gen-
eration of NO occurs in patients with type 1 diabetes
and is associated with enhanced peroxynitrite produc-
tion and lipid peroxidation (47). Furthermore, a corre-
lation between increased plasma NOx levels and
endothelial dysfunction, lower blood pressure, and sym-
pathetic nerve dysfunction in type 1 diabetes has also
been found (47,48).
In the present study, inhibition of nitrosative stress by
both LY333531 and L-NIL was associated with improve-
ments in MABP and heart rate as well as pressor responses
to vasoactive agents in STZ-diabetic rats. However, the
change in MABP in response to acute administration of
L-NAME was improved in L-NIL– but not LY333531-treated
rats. The reason for this is unclear. However, under
normal conditions as seen in control rats, administration
of L-NAME has been reported to increase MABP as a result
of an increase in total peripheral resistance caused by both
decreased NO production (largely from eNOS) and poten-
tiation of the actions of ET-1 (49). In diabetes, the ET-1–
mediated increase in MABP may be compromised by
increased iNOS activity and in the presence of L-NIL,
MABP increases. On the other hand, it is possible that
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FIG. 6. Effect of PKC2 silencing on ERK1/2 and NF-B activation in VSMC. A: Representative Western blot showing phospho-ERK-1 (Thr
202) and
phospho-ERK-2 (Tyr
204) in comparison with total ERK1/2 in VSMC treated with MOCK or PKC2 siRNA. The densitometric values of
phospho-ERK-1 were normalized to corresponding total ERK-1 densitometric values, and the relative band intensities are expressed as means 
SE (n  4 independent experiments). Open bars represent low glucose–treated and dark bars represent high glucose–treated VSMC. *P < 0.05
compared with all other groups. B: Representative Western blot showing phospho-NF-B P65 subunit (Ser
536) in comparison with total NF-B P65
in VSMC treated with MOCK or PKC2 siRNA. The densitometric values of phospho-NF-B P65 were normalized to corresponding total NF-B P65
densitometric values and the relative band intensities are expressed as means  SE (n  4 independent experiments). Open bars represent low
glucose–treated and dark bars represent high glucose–treated VSMC. *P < 0.05 compared with all other groups.
TABLE 1
General characteristics of rats after 3 weeks of LY333531 and L-NIL treatment
Parameters C D C-LY C-LNIL D-LY D-LNIL
Body weight (g)
Initial 278  4.2 253  5.0 282  6.2 292  6.3 253  4.2 270  6.0*
Final 423  5.3 360  8.2* 425  6.2 428  11.9 372  9.5* 372  13.2*
Blood glucose (mmol/l) 8.3  0.23 31.1  0.8* 8.5  0.22 7.7  0.1 31.8  0.75* 27.5  0.8*
All data expressed are means  SE. *Different from C, C-LY, and C-LNIL groups. C, control rats; D, diabetic rats; LY, LY333531.
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part because of its inhibitory actions on ET-1 (50). It is also
likely that other unknown factors contribute to the de-
pressed MABP in response to L-NAME in diabetic rats
both in the absence and presence of the inhibitors.
In conclusion, the results of the present study demonstrate
that PKC2 is an obligatory mediator of nitrosative stress and
that LY333531 signiﬁcantly reduced the formation of iNOS
and improved cardiovascular abnormalities in STZ-diabetic
rats. Moreover, hyperglycemia-induced activation of PKC2
is antecedent to increases in superoxide, ERK1/2, NF-B, and
iNOS expression in cardiovascular tissues, whereas inhibi-
tion of this pathway suppresses key signaling events that lead
to increased nitrosative stress. Collectively, our data suggest
that inhibition of PKC2 may be a useful approach for
correcting abnormal hemodynamics in diabetes by prevent-
ing iNOS-mediated nitrosative stress.
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